《大行報告》大摩:理想(02015.HK)發行美國存託股份 資本補充屬策略性利好
摩根士丹利發表研究報告指出,理想(02015.HK)宣布擬通過場內股票發行計劃發行最高20億美元的美國存託股份(ADS),集資所得擬用於研發下一代電動汽車技術,包括純電動汽車、智能座艙與智能駕駛技術,以及開發新平台。該行認為,根據市場價格每股理想約38美元計算,預期是次增發ADS涉及發行額外約5,260萬股ADS。
該行指出,儘管投資者可能憂慮理想通過場內股票發行計劃增發ADS或短期影響股價,但相信波動性應可控,資本補充屬策略性利好,加上其80億美元的現金及流動資產,即使對宏觀經濟放緩的憂慮愈來愈大,仍預期可支援理想的戰略和產品野心。對理想(LI.US)目標價41美元,評級「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.